DK1073648T3 - 12,13-Modificerede epothilonderivater - Google Patents

12,13-Modificerede epothilonderivater

Info

Publication number
DK1073648T3
DK1073648T3 DK99916383T DK99916383T DK1073648T3 DK 1073648 T3 DK1073648 T3 DK 1073648T3 DK 99916383 T DK99916383 T DK 99916383T DK 99916383 T DK99916383 T DK 99916383T DK 1073648 T3 DK1073648 T3 DK 1073648T3
Authority
DK
Denmark
Prior art keywords
epothilone derivatives
modified epothilone
modified
derivatives
epothilone
Prior art date
Application number
DK99916383T
Other languages
English (en)
Inventor
Gregory D Vite
Soong-Hoon Kim Kim
Gerhard Hofle
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1073648T3 publication Critical patent/DK1073648T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK99916383T 1998-04-21 1999-04-05 12,13-Modificerede epothilonderivater DK1073648T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8256498P 1998-04-21 1998-04-21

Publications (1)

Publication Number Publication Date
DK1073648T3 true DK1073648T3 (da) 2007-01-08

Family

ID=22171978

Family Applications (3)

Application Number Title Priority Date Filing Date
DK99916383T DK1073648T3 (da) 1998-04-21 1999-04-05 12,13-Modificerede epothilonderivater
DK99915273T DK1073647T3 (da) 1998-04-21 1999-04-05 12,13-cyclopropan epothilon-derivater
DK05015236.2T DK1589017T3 (da) 1998-04-21 1999-04-05 12,13-modificerede epothilon-derivater

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK99915273T DK1073647T3 (da) 1998-04-21 1999-04-05 12,13-cyclopropan epothilon-derivater
DK05015236.2T DK1589017T3 (da) 1998-04-21 1999-04-05 12,13-modificerede epothilon-derivater

Country Status (17)

Country Link
US (2) US6380395B1 (da)
EP (3) EP1589017B1 (da)
JP (2) JP2002512238A (da)
CN (1) CN1142923C (da)
AR (2) AR015007A1 (da)
AT (2) ATE340177T1 (da)
AU (2) AU757733B2 (da)
BR (1) BR9909795A (da)
CA (2) CA2323609A1 (da)
CY (2) CY1105836T1 (da)
DE (2) DE69933287T2 (da)
DK (3) DK1073648T3 (da)
ES (3) ES2273484T3 (da)
PE (1) PE20000460A1 (da)
PT (3) PT1073647E (da)
TR (1) TR200003036T2 (da)
WO (2) WO1999054318A1 (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2368658A1 (en) * 1999-03-29 2000-10-05 Soong-Hoon Kim A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6989450B2 (en) 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
PT1353668E (pt) 2001-01-25 2008-06-30 Bristol Myers Squibb Co Processos de preparação de substâncias farmacêutica contendo substâncias análogas à epotilona para o tratamento de cancro
BR0206511A (pt) * 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
PL363363A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BRPI0207961B8 (pt) * 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2449077A1 (en) 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
AU2002331171A1 (en) * 2001-08-23 2003-03-10 Novartis Pharma Gmbh Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6719540B2 (en) 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BR0313039A (pt) * 2002-07-31 2005-08-09 Mercian Corp Composto, medicamento, composição farmacêutica, método para prevenir ou tratar uma doença contra a qual um controle da expressão do gene é eficaz, método para prevenir ou tratar uma doença contra a qual a supressão da produção de vegf é eficaz, método para prevenir ou tratar uma doença contra a qual uma inibição da angiogênese é eficaz, uso do composto, método para produzir um composto 9-desoxi 1107, linhagem streptomyces sp. a-1543 (ferm bp-8442), método de produzir um composto 6- desoxi, e linhagem a-1544 (ferm bp-8446) ou linhagem a-1545 (ferm bp-8447)
AU2003266961A1 (en) * 2002-08-02 2004-02-25 Novartis Ag Epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RS20050235A (en) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
WO2004032866A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
JP2006504727A (ja) * 2002-10-11 2006-02-09 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド 多発性骨髄腫の処置のためのラクトン誘導体
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
RU2358729C2 (ru) * 2003-10-09 2009-06-20 Козан Байосайенсиз, Инк. Терапевтические композиции
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
SI1817013T1 (sl) * 2004-11-18 2008-12-31 Bristol Myers Squibb Co Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
EP1856255A4 (en) 2005-02-11 2010-01-27 Univ Southern California METHODS OF EXPRESSING PROTEINS WITH DISULFIDE BRIDGES
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
KR101506466B1 (ko) 2006-05-16 2015-03-27 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
PE20080316A1 (es) * 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AU2007329375A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
CA2677803A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) * 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008147941A1 (en) 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
WO2009146152A2 (en) * 2008-04-04 2009-12-03 Emory University Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment
CA2722371C (en) * 2008-04-24 2016-06-21 Bristol-Myers Squibb Company Use of epothelone d in treating tau-associated diseases including alzheimer's disease
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
JP2018534283A (ja) 2015-10-16 2018-11-22 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ エポシロン類似体、合成方法、処置方法、およびその薬物結合体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
EP0941227B2 (de) 1996-11-18 2009-10-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DK0975638T3 (da) 1997-02-25 2002-11-18 Biotechnolog Forschung Gmbh Sidekædemodificerede epothiloner
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
MXPA00007681A (es) 1998-02-05 2003-07-14 Novartis Ag Composiciones de epotilona.
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
EA009206B1 (ru) 1999-02-18 2007-12-28 Шеринг Акциенгезельшафт Производные 16-галогенэпотилона и их фармацевтическое использование
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos

Also Published As

Publication number Publication date
JP2002512239A (ja) 2002-04-23
WO1999054319A1 (en) 1999-10-28
AU3382799A (en) 1999-11-08
AR015774A1 (es) 2001-05-16
EP1073648A4 (en) 2003-01-02
CY1109593T1 (el) 2014-08-13
PT1073648E (pt) 2006-12-29
ES2327803T3 (es) 2009-11-03
CN1298398A (zh) 2001-06-06
JP4476483B2 (ja) 2010-06-09
US6380395B1 (en) 2002-04-30
WO1999054318A1 (en) 1999-10-28
DE69941083D1 (en) 2009-08-20
AU3471699A (en) 1999-11-08
EP1073647A1 (en) 2001-02-07
TR200003036T2 (tr) 2001-01-22
ES2400049T3 (es) 2013-04-05
PT1073647E (pt) 2009-07-17
EP1073648B1 (en) 2006-09-20
EP1073647A4 (en) 2003-01-02
CY1105836T1 (el) 2011-02-02
EP1073648A1 (en) 2001-02-07
DE69933287D1 (de) 2006-11-02
EP1589017A2 (en) 2005-10-26
CA2329181C (en) 2011-02-22
EP1589017B1 (en) 2012-12-05
AR015007A1 (es) 2001-04-11
CA2329181A1 (en) 1999-10-28
DE69933287T2 (de) 2007-05-03
ES2273484T3 (es) 2007-05-01
CA2323609A1 (en) 1999-10-28
AU748526B2 (en) 2002-06-06
EP1589017A3 (en) 2009-04-22
EP1073647B1 (en) 2009-07-08
US6399638B1 (en) 2002-06-04
PT1589017E (pt) 2013-03-04
BR9909795A (pt) 2000-12-26
ATE340177T1 (de) 2006-10-15
ATE435861T1 (de) 2009-07-15
DK1589017T3 (da) 2013-03-18
JP2002512238A (ja) 2002-04-23
PE20000460A1 (es) 2000-06-09
CN1142923C (zh) 2004-03-24
AU757733B2 (en) 2003-03-06
DK1073647T3 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
DK1073648T3 (da) 12,13-Modificerede epothilonderivater
ATE426598T1 (de) Epothilonderivate
DE69907964D1 (de) 1,2-annelierte chinolinderivate
NO20010193L (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
TR199802765A3 (tr) Tiyazol türevleri.
DK1140835T3 (da) 3,3-biarylpiperidin- og 2,2-biarylmorpholon-derivater
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20003825D0 (no) 1,3,4 - oxadiazolonderivater
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE233253T1 (de) Chromanderivate
ATE234839T1 (de) 4,5-azolo-oxindole
DK1060183T3 (da) 5-deoxycytidinderivater
ATE243218T1 (de) 2''-deoxyhygromycinderivate
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
DE69805392T2 (de) Thiazol-Derivate